The author has carried out a series of experimental studies and clinical trials on local administration of antitumor agents for advanced malignancies in the areas of head, neck and chest.<br>A clinical trial with intra-arterial one-shot administration of tumor inhibiting agents through a polyethylene tube indwelt in the stemartery has proved to make it possible to administer a larger dose of the agents in a longer period than intravenous use. Particularly, 14 percent of 86 patients with advanced malignancies placed on intra-arterial mitomycin C survived 18 months or more, while control group placed on intravenous mitmycin C alone expired within 12 months.<br>A continuous intra-arterial infusion has also been effectively tried on cases of advanced malignancies developed in areas of head and neck, using mitomycin C, cyclophosphamide and amethopterine by means of an infusion pump devised by the author. Selection of antidotes against the agents infused is one of important problems in intra-arterial infusion. It is revealed that sodium thiosulfate and Vitamin B6 have efficacy to inactivate the activities of antitumor agents in vivo both in animal experimentations and on clinical cases.<br>Standard regional tumor perfusions with cancerocidal chemotherapeutics have been also tried effectively on malignancies in face and head. However, there are left many cases with malignancies in neck and chest to which regional tumor perfusion is not applicable. The author has developed a new method named differential tumor perfusion in which the blood circulation of the upper half body is maintained by the proper heart and lung of the patient under hyperthermic condition keeping high level of the antitumor agent, and that of the lower half body is maintained under hypothermic condition by means of an extracorporeal circulation technique. Details of clinical responses of the patients following the differential tumor perfusion are summerized with analysis of the biological changes in the peripheral blood, bone marrow, renal and hepatic functions.<br>Furtheremore, the author reports a total body perfusion technique with antitumor agents in combination with exchange blood-transfusion and bone marrow auto-transplantation.<br>Thirteen out of 15 cases with advanced malignancies (either primary or metastatic) responded favourably the differetial tumor perfusion, revealing relief of subjective complaints, and there were also noticed tumor regression in 6 cases. However. the survival time of the patients undergone the differential tumor perfusion seems not to have been prolongeded remarkably.<br>In conclusion, it is said that regional tumor perfusion for head and neck malignancies depends on whether more effective agents will be developed in the future.